PMID- 26676456
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151218
LR  - 20151217
IS  - 1757-5664 (Print)
IS  - 1757-5664 (Linking)
VI  - 4
IP  - 1
DP  - 2012 Jan
TI  - Difficult Urination Does Not Affect the Successful Outcome after 100U 
      OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor 
      Overactivity.
PG  - 29-34
LID - 10.1111/j.1757-5672.2011.00102.x [doi]
AB  - OBJECTIVES: Intravesical injection of onabotulinumtoxinA (i.e. Botox) provides 
      effective treatment for overactive bladder. However, treatment-related adverse 
      events (AEs) remain problems. This study investigated the effect of AEs after 
      onabotulinumtoxinA injection on the success rate for idiopathic detrusor 
      overactivity (IDO). METHODS: A total of 174 patients who received the first 
      single intravesical onabotulinumtoxinA 100U injection for refractory IDO were 
      included. The onabotulinumtoxinA related AEs including acute urinary retention 
      (AUR), large postvoid residual (PVR, >/=150 mL), difficult urination, urinary tract 
      infection, gross hematuria and general weakness were recorded. The success rate 
      was determined based on patient perception of bladder condition improved by two 
      scales. The short-term (3 months) and long-term (up to 24 months) success rates 
      were analyzed according to the occurrence of these AEs. RESULTS: A successful 
      outcome was reported by 138 (79.3%) patients at 3 months. AUR occurred in 12 
      (6.9%) patients, large PVR developed in 81 (46.6%) and 73 (42%) needed straining 
      to void. Gross hematuria occurred in 17 (9.8%) patients, urinary tract infection 
      developed in 27 (15.5%) and general weakness was noted in 6 (3.4%). The 
      occurrence of AUR did not affect the therapeutic results. Patients having large 
      PVR and difficult urination had a significantly higher success rate at 3 months. 
      Long-term success rates up to 24 months showed no significant difference between 
      patients with and without AEs. CONCLUSIONS: AEs after intravesical 100U 
      onabotulinumtoxinA for IDO were frequently encountered. However, the occurrence 
      of AUR, large PVR or difficult urination did not affect the final therapeutic 
      outcome.
CI  - (c) 2011 Blackwell Publishing Asia Pty Ltd.
FAU - Chen, Yih-Chou
AU  - Chen YC
AD  - Department of Urology, Hualien Hospital, Hualien, TaiwanDepartment of Urology, 
      Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Hualien Hospital, Hualien, TaiwanDepartment of Urology, 
      Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20110912
PL  - Australia
TA  - Low Urin Tract Symptoms
JT  - Lower urinary tract symptoms
JID - 101506777
OTO - NOTNLM
OT  - adverse events
OT  - detrusor overactivity
OT  - onabotulinumtoxinA
OT  - overactive bladder
EDAT- 2012/01/01 00:00
MHDA- 2012/01/01 00:01
CRDT- 2015/12/18 06:00
PHST- 2015/12/18 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2012/01/01 00:01 [medline]
AID - 10.1111/j.1757-5672.2011.00102.x [doi]
PST - ppublish
SO  - Low Urin Tract Symptoms. 2012 Jan;4(1):29-34. doi: 
      10.1111/j.1757-5672.2011.00102.x. Epub 2011 Sep 12.